Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure.
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Meta-analysis finds Cimlanod does not reduce mortality in HFrEF, increases hypotension risk
Cimlanod did not reduce death in heart failure patients
This meta-analysis of 459 patients with HFrEF found that Cimlanod did not significantly reduce all-cause or cardiac mortality compared to pl…
A meta-analysis of heart failure patients found Cimlanod did not lower death risk and increased the chance of low blood pressure symptoms.
Vericiguat showed no significant effect on flow-mediated dilation in a small pilot trial of 26 heart failure patients.
Pilot trial shows vericiguat may lower heart failure blood pressure markers
This pilot, randomized, double-blind, placebo-controlled trial enrolled 26 patients with heart failure with reduced ejection fraction (HFrEF…
A small pilot trial found vericiguat reduced a heart failure blood pressure marker, though the study was too small to confirm this benefit.
Higher Lactate Dehydrogenase-to-Albumin Ratio Associated With Increased Readmissions and Mortality in Heart Failure
High Blood Marker Tied to Worse Heart Failure Outcomes
This retrospective cohort study included 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction. Hi…
A new blood marker combo can spot heart failure patients most likely to get worse — helping doctors act sooner.
Observational study reveals 'tug-of-war' contraction patterns in healthy and infarcted hearts
New research reveals a hidden heart tug-of-war that causes failure
This observational study describes mesoscale contraction patterns in healthy individuals and patients with myocardial infarction. The author…
A hidden tug-of-war inside your heart explains why some pumps fail while others keep going strong during stress.
Qiliqiangxin capsule adjunctive therapy reduces cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction.
A Traditional Chinese Capsule Meets Modern Heart Failure Trials
This systematic review and meta-analysis evaluated Qiliqiangxin capsule as adjunctive therapy in 5,580 patients with heart failure with redu…
Adding a traditional Chinese medicine capsule to standard heart failure care reduced deaths and hospital stays in a review of 24 trials.
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care.
A Simple Chatbot After Heart Failure Hospitalization May Keep You Healthier and Out of the Hospital
This randomized controlled trial enrolled 66 patients with heart failure with reduced ejection fraction (HFrEF) recently discharged from the…
For people with heart failure, consistent digital check-ins after leaving the hospital could be the key to getting the right medication stre…